Jazz Pharmaceuticals (JAZZ) Income from Continuing Operations (2010 - 2026)

Jazz Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 293100000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 418.59% year-over-year to 293100000.0; the TTM figure through Mar 2026 stood at 29695000.0 (down 93.85% YoY), while the FY2025 annual figure was 355416000.0, down 163.27% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 293100000.0, up from 203514000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 293100000.0 in Q1 2026, with the low at 718354000.0 in Q2 2025.
• The 5-year median for Income from Continuing Operations is 94626000.0 (2023), against an average of 41365529.41.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 641.44% in 2022, then soared 1116.53% in 2023.
• Jazz Pharmaceuticals' Income from Continuing Operations stood at 239951000.0 in 2022, then surged by 139.44% to 94626000.0 in 2023, then jumped by 102.0% to 191148000.0 in 2024, then advanced by 6.47% to 203514000.0 in 2025, then soared by 44.02% to 293100000.0 in 2026.
• Business Quant data shows JAZZ's Income from Continuing Operations at 293100000.0 in Q1 2026, 203514000.0 in Q4 2025, and 251435000.0 in Q3 2025.